Natco Pharma’s arm Natco Pharma (Canada) Inc. has reached a settlement with Celgene, which has become a part of Bristol-Myers Squibb, for Lenalidomide capsules in Canada. The terms of the agreement are confidential, as per the agreement, a statement on Friday from Natco Pharma on the settlement said. The drug is the generic of Celgene’s Revlimid indicated in the treatment of multiple myeloma. In 2015, Natco Pharma and its U.S. partner Allergan had reached a settlement with Celgene in a patent infringement case pertaining to Revlimid in the U.S. Under this, Natco is to receive a volume-limited licence to sell Lenalidomide in the U.S. from March 2022 and begin unlimited sale from January 2026.
The Hyderabad-headquartered drugmaker had recently said it was expecting approval for Lenalidomide in the US. Natco Pharma shares closed at ₹679.75 apiece, with a gain of less than 1%.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Faster pages
Move smoothly between articles as our pages load instantly.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Personalised recommendations
A select list of articles that match your interests and tastes.
Briefing
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear reader,
We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.
Support Quality Journalism
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath